Odyssey Therapeutics, Inc. (ODTX) financial statements and ratios from SEC XBRL: revenue $2.98M (TTM), net margin -4994.9%, revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $2.98M |
| Net Margin | -4994.9% |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | -94.1% |
| FCF Growth (YoY) | 2.8% |
| Price / Book | 2.81 |
| Price / Sales | 1236.29 |
| FCF Yield | -19.6% |
| Altman Z-Score | -3.19 (distress) |
| Sector P/E (Healthcare) | 21.6 |
ODTX overview · ODTX earnings · ODTX KPIs · ODTX investor relations · ODTX ownership · ODTX peers · ODTX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.